📅 PUBMED DAILY TRIAGE — 2026-05-30

Window: 2026-05-29T09:00:00Z → 2026-05-30T09:00:00Z (CRDT) Topics scanned: 10 | Candidates reviewed: ~100 | Articles classified: 20 High priority: 3 | Standard: 17 | Low/excluded: ~19 | Unsolicited finds: 0 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

TR-001 / PMID 42215593 · Early detection of gastric cancer: a novel circulating microbiome DNA based liquid biopsy assay · 8/10 🔴 EARLY_CANCER_DETECTION

cmDNA-based ML model achieves AUC 0.914 in multicenter independent validation (n=885 total), including AUC 0.792 for Stage I GC — a novel liquid biopsy modality targeting the microbiome rather than ctDNA, with stage-shift evidence. Further prospective clinical validation needed before deployment. (NPJ Precis Oncol; Chen Y et al.)

CBC-Based Diagnostics & ML in Hematology | Aging, Longevity, Population Health

TR-002 / PMID 42215477 · Latent biochemical phenotypes delineate divergent health trajectories in older adults · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE

ML applied to 39 routine blood biomarkers (no specialized assays) identifies three aging phenotypes in n=1,491 with 10-year follow-up; Metabolic phenotype predicts mortality (HR=1.49 in women), partially replicated in independent EXERNET cohort. Scalable, low-cost precision prevention using universally available labs. CBC/ML zero-streak broken (day 3). (NPJ Aging; González-Martos R et al.)

Rare Diseases with High Unmet Need

TR-003 / PMID 42212672 · Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials · 8/10 🟠 NOVEL_TREATMENT

Phase 3 RCT (n=406) of anselamimab (anti-amyloid fibril mAb) in advanced AL amyloidosis: primary endpoint NOT MET overall (win ratio 1.11, p=0.332), BUT kappa isotype subgroup (n=72) showed 62% ACM reduction (HR 0.38, p=0.012) and 71% CVH reduction (IRR 0.29, p=0.028). Lambda population: no benefit. Signals biomarker-stratified treatment potential in a high-unmet-need rare disease. ⚠️ Exploratory subgroup — not yet practice-changing. (JCO; Wechalekar AD et al.)

🟢⚪ STANDARD (4–7) — Top by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

• TR-004 / PMID 42216090 · A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed/refractory B-cell malignancies · 7/10 · J Hematol Oncol — Phase Ia, n=15, ORR 30%, no CRS, novel T-cell-independent B-cell depletion mechanism
• TR-006 / PMID 42215353 · AI for the assessment and discovery of morphological-molecular biomarker relationships in hematologic malignancies · 6/10 · Blood Reviews — Comprehensive review; AI morphology linked to molecular alterations; expert-level DL classification
• TR-010 / PMID 42215456 · Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies · 5/10 · Blood Cancer J — Review; cardio-oncology framework for MM era therapies; MD Anderson authorship

Novel Therapeutics: Immunotherapy, CAR-T, Targeted Therapy

• TR-005 / PMID 42215447 · Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies · 6/10 · Nat Commun — Mechanistic insight: T-DXd exploits adaptive HER2 upregulation in ALK+ NSCLC residual disease niches; mixed model (non-human cap applied)

AI/ML in Clinical Diagnostics and Imaging

• TR-007 / PMID 42215698 · A multimodal interpretable deep learning-radiomics framework for predicting lymph node metastasis following neoadjuvant CRT in locally advanced rectal cancer · 6/10 · NPJ Precis Oncol — Multicenter validated; interpretable framework; surgical decision support
• TR-012 / PMID 42215932 · MSTM-Net: a two-stage prostate cancer segmentation network based on Swin-Transformer-Mamba architecture · 5/10 · BMC Med Imaging — Dice 63.89% lesion segmentation; cross-dataset validation on PI-CAI; AI/imaging

Precision Oncology and Genomic Medicine

• TR-011 / PMID 42216188 · Advances in the molecular subtyping of gastric cancer · 5/10 · World J Surg Oncol — TCGA/ACRG review; pairs thematically with TR-001 (cmDNA gastric cancer detection)
• TR-016 / PMID 42215741 · SQLE as a potential diagnostic and prognostic biomarker for LIHC: a multi-cohort and spatial study · 5/10 · NPJ Precis Oncol — Multi-cohort spatial transcriptomics; cholesterol synthesis vulnerability in HCC

Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

• TR-008 / PMID 42216231 · Metformin versus DPP-4 inhibitors and risk of parkinsonism in type 2 diabetes: active-comparator cohort with landmark design · 6/10 · Diabetol Metab Syndr — n=151,070 PS-matched; primary null result; exploratory 10-yr signal (aHR 0.85) hypothesis-generating; rigorous design
• TR-009 / PMID 42216136 · C-reactive protein-to-albumin ratio and the mortality of patients with heart failure: a meta-analysis · 6/10 · BMC Cardiovasc Disord — n=6,377; RR=2.34 for high CAR; prospective RR weaker (1.45); needs validation

Aging, Longevity, and Population Health

(TR-002 PMID 42215477 is primary HIGH entry for this topic)

• TR-020 / PMID 42215252 · Precision medicine 'versus' or 'for' public health? Different configurations of PM in relation to SDH · 4/10 · Soc Sci Med — Qualitative policy analysis; USA PMI + UK 100KGP; equity framing

Rare Diseases with High Unmet Need

(TR-003 PMID 42212672 is primary HIGH entry for this topic)

• TR-014 / PMID 42212615 · Expanding the Utility of Exome Sequencing in Preventive and Population Genetics · 5/10 · Am J Med Genet A — Rare disease genomic screening utility expansion; Greece cohort
• TR-017 / PMID 42212497 · Genetic Insights Into AVP Deficiency: Identification of a Novel AVP Variant and Curated Catalogue of Pathogenic Variants · 4/10 · Clin Genet — Rare endocrine disease; diagnostic resource; central diabetes insipidus

Early Cancer Detection (additional standard entries)

• TR-015 / PMID 42215863 · Multiplexed Peptide-Based Fluorescent Probe Platform for Analysis of HER2-Positive Exosomal Membrane Proteins · 5/10 · Anal Chem — Novel sensing modality; pilot human plasma/urine; primarily in vitro

CBC-Based Diagnostics & ML (additional)

• TR-013 / PMID 42216189 · Aspiration to architecture: multi-omics, AI, digital twins, and blockchain for P4 medicine · 5/10 · J Transl Med — Conceptual framework + n=2,072 metabolomics pilot; commercial COI (Theriome Inc.)

💡 UNSOLICITED FINDS

None today. All sentinel scan top-10 PMIDs overlapped with existing watchlist topic coverage. 1,291 sentinel candidates were available; top 10 reviewed by CRDT.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 7
• Treatment Innovation: 5
• Genomics/Precision Medicine: 4
• Prevention: 2
• Public Health: 2

By evidence maturity:

• Exploratory: 12
• Validated: 7
• Potentially Practice-Changing: 1 (⚠️ conditional on kappa isotype subgroup for TR-003)

By watchlist topic (reviewed / kept ≥4 / highest score):

By source type: peer_reviewed: 20 | preprint: 0

Topics with zero 8+ articles today:

• Hematologic malignancies (best: 7/10 — PSB202 Phase Ia)
• AI/ML in clinical diagnostics and imaging (best: 6/10)
• Precision oncology and genomic medicine (best: 5/10)
• Novel therapeutics: immunotherapy, CAR-T, targeted therapy (best: 6/10)
• Cardiovascular-metabolic (best: 6/10)

🔧 RUN NOTES

• Window expansion: NOT triggered. All 10 topics returned ≥5 records. Rare disease topic returned 13 raw results (adequate).
• CBC/ML zero-streak: BROKEN. Previous 2 days (2026-05-28, 2026-05-29) had zero HIGH in this topic. Today PMID 42215477 (NPJ Aging, routine blood panel ML) scores 8/10 and qualifies. Note: matched via blood biomarker clustering rather than strict CBC focus.
• Anselamimab CARES (PMID 42212672): Indexed 2026-05-29 at 08:03 UTC (before window start) but PMID not found in previous run fingerprints; included per fingerprint deduplication rule.
• Truncation: AI/ML diagnostics (160 raw), Novel therapeutics (144 raw), Cardiometabolic (202 raw), Sentinel (1,291 raw) all truncated to top 10 by CRDT ordering. Higher-priority records may exist beyond first 10 in high-volume topics; consider stricter query refinement for AI/ML topic in future runs.
• humans[MeSH] filter: Applied to Aging/longevity topic as per v1.2 correction. Reduced from estimated 150+ to 60 results; successfully avoided non-human noise.
• Multiple NPJ Precis Oncol batch publications (2026-05-29): PMIDs 42215593, 42215698, 42215704, 42215741, 42215608 — 5 NPJ Precis Oncol articles indexed same day; likely batch issue. Quality varied (5–8/10).
• Haematological phenotype thrombosis signal: TR-002 (42215477) reports thrombosis HR=7.20 in Haematological phenotype men (p=0.018) — striking subgroup finding worth flagging for downstream pipeline attention despite being a secondary analysis endpoint.
• Rolling 7-day view (state-based): Topics consistently producing zero HIGH: Precision oncology (0 HIGH in last 3 runs of state), AI/ML diagnostics (0 HIGH in last 3 runs). CBC/ML topic had 0 for 2 consecutive days before today.